Lilly Ventures and Mitsui Global Investment reinvested in a $30m round for Symic that will support a phase 3 trial for a compound intended to improve vein graft surgery.
US-based biopharmaceutical company Symic Bio has completed a $30m series B round backed by all its existing investors including the corporate venturing units of pharmaceutical company Eli Lilly and diversified conglomerate Mitsui.
Lilly Ventures and Mitsui Global Investment were joined by Danish state-backed fund Den Danske Forskningsfond, Ally Bridge Group, InCube Ventures, Purdue Foundry Investment Fund, Mission Bay Capital, QB3 Partners and new investor Heda Ventures
Symic is working on a new type of therapeutics called matrix regulators. It will…
